CP-91149 is a selective glycogen phosphorylase (GP) inhibitor with IC50 of 0.13 μM in the presence of glucose, 5- to 10-fold less potent in the absence of glucose.
C, experimental design illustrating the time points in which PYGL inhibitor CP-91149 (GPi) and 2DG were added to the groups depicted in D to J. D, representative images of cell invasion through the Boyden chamber from control, 2DG and recovery GBM1 treated with GPi or DMSO. E to G, comparison of the invasive capacity of EV or shG6PC in the presence or absence of GPi.
Tipiracil is an inhibitor of thymidine phosphorylase, the enzyme that degrades trifluridine into trifluorothymidine. Its combination with trifluridine increases the bioavailability of trifluridine.
Doxifluridine is an oral prodrug that is converted to the cytotoxic agent 5-fluorouracil (5-FU).